GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Research output: Contribution to journalArticle

Abstract

Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
Original languageEnglish
Pages (from-to)340-347
JournalCurrent Diabetes Reports
Volume7
Issue number5
Publication statusPublished - 2007
Publication categoryResearch
Peer-reviewedYes